Why it stays S-tier, and what that means
BPC-157 stays an editorial favorite at Protocol One. That is a statement of our interest in its recovery research, not a clinical evidence grade or a recommendation to use it. Animal findings and personal reports are reasons to investigate; they do not settle whether a treatment works or is safe for people.
- Editorial tier
- S-Tier
- Human evidence
- Limited; not established care
- US approval
- Not FDA-approved
- Safety
- Human safety remains uncertain
A 2025 systematic review in orthopaedic sports medicine, searching literature through June 3, 2024, included 35 preclinical studies and one retrospective clinical study. Its authors found insufficient clinical safety data to establish practice guidelines. That review is a dated evidence snapshot, not proof that no later studies exist.
The FDA's compounding safety assessment identifies limited safety information and concerns about immunogenicity and peptide-related impurities. A prescription, vendor claim or certificate of analysis does not turn BPC-157 into an FDA-approved medicine.
Evidence summary and linked FDA status checked October 7, 2026 by Protocol One editorial. Not a clinician review. Discuss treatment decisions with a licensed clinician.
What people use it for
Explore the research questions below. These are areas of investigation, not established treatment indications:
- Tendinitis The most-discussed use, rooted in the foundational rat-tendon data
- Rotator cuff Stubborn shoulder injuries that stall in physical therapy
- Achilles tendon Where the biomechanical-strength animal study focused
- Plantar fasciitis Persistent foot and heel cases that resist rest
- Gut healing & IBS The original discovery, it heals the gut lining in animal models
- Post-surgery recovery Investigated for tissue repair after operations
Access and source claims
BPC-157 is not FDA-approved. The FDA currently lists it in the section for bulk substances whose nominations were withdrawn, with safety concerns still described. That is different from an approval or a blanket statement that compounding is permitted.
A clinic or vendor's availability claim is not proof of lawful access, efficacy or safety. Ask a licensed clinician and pharmacist about the applicable rules, what evidence supports the proposed use, and established alternatives. Research-use products are not a substitute for approved treatment.
A certificate of analysis can report tests on a sample; it cannot establish human safety or verify that every vial is sterile or authentic. Read the source-document questions before relying on a vendor's claims.
New to peptides? Start with the foundations ->
Two studies worth reading
Tendon healing - the foundational paper
Gwyer et al., Cell and Tissue Research
Rats with surgically transected Achilles tendons healed faster on systemic BPC-157 than controls. The biomechanical strength tests at 14 days were the headline finding.
Gut lining and ulcer healing
Sikiric et al., Curr Pharm Des
A review covering the gut-protective mechanism, including its role in NSAID-induced ulcer recovery. A discussion of proposed mechanisms, including blood-vessel growth in preclinical models.
Watch: Andrew Huberman on peptides (2024 solo episode)
Huberman's 2-hour solo episode on peptide therapeutics is the most rigorous mainstream coverage of BPC-157, Thymosin beta-4, and the growth-hormone-releasing peptides. He covers sourcing, dosing, routes of administration, and the evidence gaps honestly. Worth listening end to end if you are considering any peptide for tissue recovery.
Watch: Huberman on peptides (June 2026)
BPC-157 gets the most airtime in the June 2026 episode. Dr. Abud Bakri and Huberman walk through the animal-data-to-human-data gap, the tumor and angiogenesis question, and the 2023 FDA reclassification that changed how it can legally be sourced. The most grounded mainstream coverage of the peptide to date.
Source: Huberman Lab - Peptides: The Science, Uses & Safety (Dr. Abud Bakri). See our full decode of what he says about every peptide.
Evidence summary updated · 2026·10·07 · See source dates above